Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV : A systematic literature review and network meta‐analysis
Rattachement africain : us, th. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: This study evaluated rates of treatment-emergent resistance-associated mutations (TE-RAMs) and discontinuation due to adverse events (DC-AEs) across integrase strand transfer inhibitor (INSTI)-based single-tablet regimens and injectable cabotegravir + rilpivirine (CAB + RPV) in virologically suppressed people with HIV. METHODS: A systematic literature review was conducted for phase 2-4 randomized controlled trials with ≥48 weeks of follow-up involving virologically suppressed people with HIV aged ≥12 years and published January 2003-March 2024. A random-effects network meta-analysis estimated comparative rates of TE-RAMs and DC-AEs among regimens at 48 weeks. Risk of bias and strength of evidence were assessed using Cochrane RoB and CINeMA, respectively. RESULTS: Fourteen (7509 participants) and nine (4656 participants) studies were included in the TE-RAMs and DC-AEs analyses, respectively. No significant differences in rates of TE-RAMs were observed; risk ratios (RRs) for TE-RAMs for bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF), dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) and CAB + RPV every 4 weeks (Q4W) versus CAB + RPV every 8 weeks (Q8W) were 0.22 (95% CI, 0.02-2.04), 0.22 (95% CI, 0.00-19.85) and 0.40 (95% CI, 0.14-1.09). Compared with CAB + RPV Q4W and Q8W, DC-AEs were significantly lower with B/F/TAF (RR, 0.15 [95% CI, 0.03-0.75] and RR, 0.16 [95% CI, 0.04-0.67], respectively) and DTG/ABC/3TC (RR, 0.05 [95% CI, 0.01-0.48] and RR, 0.05 [95% CI, 0.01-0.46], respectively). CONCLUSIONS: In virologically suppressed people with HIV, switching to CAB + RPV Q8W yielded a non-significant increased risk of TE-RAMs compared with INSTI-based 2- and 3-drug regimens and CAB + RPV Q4W. Both CAB + RPV Q4W and Q8W had significantly higher risks of DC-AEs than B/F/TAF and DTG/ABC/3TC. Findings highlight the importance of considering both resistance and tolerability when switching regimens.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with <scp>HIV</scp> : A systematic literature review and network meta‐analysis
- Date Crossref
- 27/05/2025
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Utah Department of Pharmacotherapy pays non établi dans la noticeUniversité ou école supérieure
-
Gilead Sciences (United States) pays non établi dans la noticeEntreprise
-
Naresuan University pays non établi dans la noticeUniversité ou école supérieure
-
Midway University pays non établi dans la noticeUniversité ou école supérieure
-
Nova Southeastern University pays non établi dans la noticeUniversité ou école supérieure
-
Henry Ford Health pays non établi dans la noticeOrganisation à but non lucratif
-
MultiCare Health System pays non établi dans la noticeÉtablissement de santé
-
Southeast Louisiana Veterans Health Care System pays non établi dans la noticeÉtablissement de santé
-
VA Salt Lake City Healthcare System pays non établi dans la noticeÉtablissement de santé
-
Inc. Foster City California USA Gilead Sciences pays non établi dans la noticeEntreprise
-
The Research Unit of Evidence Synthesis (TRUES) Faculty of Pharmaceutical Sciences The Research Unit of Evidence Synthesis (TRUES) pays non établi dans la noticeUniversité ou école supérieure
-
Midway Specialty Care Center Fort Pierce Florida USA pays non établi dans la noticeInstitution
Department of Pharmacotherapy — University of Utah, Gilead Sciences (United States) et Naresuan University, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.